14 April 2026
The One Health Summit showcased important discussions on health sovereignty and climate-related health challenges worldwide.
17 March 2026
Learn about the HIV prevention shot lenacapavir and why Aspen Pharmacare emphasises guaranteed demand for local production.
16 March 2026
Learn about potential Aspen Pharmacare asset disposals aimed at optimising the company's global operations for greater profitability.
7 March 2026
Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.
23 January 2026
The AIDS drug tender reveals challenges in supply continuity due to Avacare subsidiaries entering business rescue.
19 January 2026
Aspen Pharmacare is lining up a generic semaglutide launch in Canada, promising big discounts, and widening GLP-1 access.
15 January 2026
Aspen Pharmacare business sale boosts investor confidence. A strategic pivot following a turbulent 2025 rebuilds financial flexibility.
14 January 2026
Aspen APAC divestment unlocks R26.5bn in capital, sharpening the group’s focus on GLP-1 injectables and reducing net debt heading into 2026.
9 January 2026
HIV prevention in South Africa hinges on local drug manufacturing to ensure access, reduce delays, and enable regional health security.
7 November 2025
Aspen Pharmacare resolves its mRNA dispute with a R500m settlement, stabilising its earnings and share price significantly.
5 November 2025
Aspen's Mounjaro expansion plans promise to enhance diabetes and weight management treatment in Sub-Saharan Africa soon.